USC Norris Comprehensive Cancer Center - Keck School of Medicine
University of Southern California
Los Angeles, CA
Filters
Save & Share
Clear Filters
Diagnosis
Purpose of Trial
Filter and find trials based on their purpose.
Risk Level
Enter this patient's risk level (IPSS-R / IPSS-M).
Accepting patients
SELECT MDS-1
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Learn more- Hypomethylating Agents (HMA)
- RAR-α / NR1B1
- Phase 3
Accepting patients
Venetoclax in Combination With ASTX727
Venetoclax in Combination With ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): A Randomized, Phase 2 Trial
Learn more- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- Phase 2
Accepting patients
Curcumin vs. Placebo
A Phase 2, Double-blind, Randomized Study to Compare the Effect of Curcumin Versus Placebo on Inflammatory Cytokines, Symptoms and Disease Parameters in Clonal Cytopenia of Undetermined Significance (CCUS), Low-Risk Myelodysplastic Syndrome (LR-MDS), and Myeloproliferative Neoplasms (MPNs)
Learn more- Placebo
- Randomization
- Phase 2